The recognition that atherosclerosis represents an inflammatory disease has begun to shift interest towards novel therapies that could specifically target the underlying inflammatory component of atherogenesis. Like low-density lipoprotein, an ideal new drug target would be a modifiable plasma risk factor that not only reflects the ongoing inflammatory process but also actively promotes it. Lipoprotein-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new risk factor that may have the potential to fulfil these requirements. © 2001 Elsevier Science Ltd.
Macphee, C. H. (2001, April 1). Lipoprotein-associated phospholipase A2: A potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology. Elsevier BV. https://doi.org/10.1016/S1471-4892(01)00024-8